QPPV.COM KNOWLEDGE ASSESSMENT

Pemivibart: Classification, Mechanism and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Pemivibart: Classification, Mechanism and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A recipient experiences anaphylaxis after an infusion. What does the fact sheet indicate about further pemivibart administration?

Continue at a slower rate after symptoms resolve Give the next dose early to maintain prophylactic coverage Do not administer further pemivibart after anaphylaxis or a severe systemic reaction Give further doses only if the next infusion is premedicated

Question 2 of 10 How should laboratory neutralisation titres and susceptibility results be used when reviewing an individual case?

They prove whether an individual was protected, regardless of exposure or host factors They should be ignored because laboratory results have no pharmacological relevance They inform biological activity but do not establish an individual’s protection with certainty They substitute for documenting the clinical course and treatment

Question 3 of 10 A patient has moderate-to-severe immune compromise but is currently infected with SARS-CoV-2. What is the most appropriate interpretation of pemivibart’s EUA scope?

The patient is eligible because immune compromise is the only relevant criterion The patient is eligible if the infection is asymptomatic The patient is outside the authorised pre-exposure prophylaxis use while currently infected The patient may receive pemivibart as treatment because the antibody targets the virus

Question 4 of 10 A patient develops a positive SARS-CoV-2 test after receiving pemivibart. Which initial pharmacovigilance interpretation is most appropriate?

The positive test proves pemivibart failed to bind the virus The positive test establishes that the patient was ineligible at administration The breakthrough alone does not prove neutralisation failed; exposure, timing, host factors, dose interval and viral susceptibility may be relevant The positive test should be excluded from assessment because the product is prophylactic

Question 5 of 10 Why should anaphylaxis, other hypersensitivity, and non-allergic infusion reactions be documented as distinct event phenotypes?

They are interchangeable terms, but separate coding improves database searches Only anaphylaxis is reportable, so distinguishing the events is unnecessary Non-allergic infusion reactions always indicate viral resistance They represent clinically different event types, and collapsing them can obscure the nature and severity of the reaction

Question 6 of 10 A person is described simply as “immunocompromised.” What is the most appropriate next step when considering whether pemivibart’s EUA applies?

Treat the description as sufficient because all immune compromise meets the EUA criteria Assess eligibility using the current FDA fact sheet, including degree of immune compromise, likely vaccine response, age, weight, infection status, and exposure status Assess only the person’s vaccination history because other criteria are advisory Use pemivibart if the person requests it, because the EUA has no defined population

Question 7 of 10 Which set of information is most relevant to document for a suspected infusion-related adverse reaction?

Infusion rate, onset relative to infusion, symptoms, treatment, and whether the infusion was stopped or restarted Only the patient’s diagnosis and whether the infusion was completed Only the variant circulating in the patient’s region The patient’s vaccination history, without details of the reaction

Question 8 of 10 Which interpretation best reflects the relationship between susceptibility evidence and national variant frequency under the EUA?

Laboratory susceptibility for one lineage is sufficient to authorise use regardless of how common resistant variants are National variant frequency is a permanent measure that need not be reassessed Susceptibility evidence and surveillance together inform whether the national frequency condition for use is met The threshold determines the dose interval rather than whether the EUA supports use

Question 9 of 10 Which statement correctly describes the authorised role of pemivibart in relation to vaccination and post-exposure use?

It replaces recommended COVID-19 vaccination and is authorised after known exposure It is authorised for treatment but not prevention It is authorised for any immunocompromised person as a substitute for vaccination It is not a substitute for recommended vaccination and is not authorised for treatment or post-exposure prophylaxis

Question 10 of 10 Which regimen is described in the article for the authorised prophylactic use?

A single 450 mg subcutaneous dose each month 4,500 mg by intravenous infusion, repeated every three months 4,500 mg by oral administration every three months A weight-based intravenous dose given only after exposure

Pemivibart: Classification, Mechanism and Pharmacovigilance — Knowledge Assessment

Cookie Settings